You are here

SB-525

Pfizer and Sangamo Dose First Participant in Phase 3 Study Evaluating Hemophilia A Gene Therapy Treatment SB-525

Drugs.com

Wed, 10/7/20 - 11:33 pm

Sangamo Therapeutics

clinical trials

giroctocogene fitelparvovec

Sangamo keeps pressure on rivals with updated hemophilia data

Biopharma Dive

Sat, 12/7/19 - 11:48 pm

Sangamo backs up early success for hemophilia gene therapy

Biopharma Dive

Sat, 07/6/19 - 01:36 pm

Spark Therapeutics

Does Sangamo Have the Best Gene Therapy Program Now?

Motley Fool

Wed, 04/3/19 - 12:28 pm

Sangamo Therapeutics

Sangamo Stock Soars on Positive Hemophilia Treatment Trial

TheStreet.com

Tue, 04/2/19 - 11:59 am

Sangamo BioSciences

clinical trials

3 Biotech Stocks That Skyrocketed This Past Week

Motley Fool

Mon, 09/4/17 - 10:07 am

Abeona Therapeutics

Sangamo BioSciences

Juno Therapeutics

Pfizer expands gene therapy effort on hemophilia, bagging rights to a Sangamo drug in a $545M deal

Endpoints

Thu, 05/11/17 - 11:21 am

Sangamo BioSciences